Skip to main
ABEO

Abeona Therapeutics (ABEO) Stock Forecast & Price Target

Abeona Therapeutics (ABEO) Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 67%
Buy 33%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Abeona Therapeutics Inc. is projected to achieve approximately $32 million in top-line revenue for 2025, with significant expected growth to $130.4 million by 2026, suggesting a strong upward trajectory in financial performance. The company benefits from a favorable market access situation that is anticipated to improve, potentially enhancing revenue generation beyond current forecasts. Additionally, the promising pipeline of gene therapies and plasma-based products aimed at treating rare genetic diseases positions the firm for further incremental upside, supporting a positive outlook for its stock performance.

Bears say

Abeona Therapeutics Inc faces significant risks that contribute to a negative outlook, primarily related to the anticipated market performance and strategic execution of its leading product, pz-cel. Slow adoption rates in the U.S. market and challenges in realizing its potential value outside of the U.S. further exacerbate concerns, alongside the possibility of setbacks in the development of its earlier-stage pipeline programs. Additionally, the potential for long-term dilution poses a financial risk that may deter investor confidence, compounding the company's challenges in stabilizing its financial position.

Abeona Therapeutics (ABEO) has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 33% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Abeona Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Abeona Therapeutics (ABEO) Forecast

Analysts have given Abeona Therapeutics (ABEO) a Strong Buy based on their latest research and market trends.

According to 3 analysts, Abeona Therapeutics (ABEO) has a Strong Buy consensus rating as of Feb 7, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $20, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $20, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Abeona Therapeutics (ABEO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.